Negotiation Timeline

  • Initiation

    A drug is identified and brought into a pCPA process (see standard negotiation process or expedited negotiation pathways).

  • Consideration

    The pCPA considers the evidence (including HTA reimbursement recommendations) and gathers other data to inform the negotiation approach, in alignment with the needs of public drug plans. This phase concludes when the pCPA sends a letter of engagement to the manufacturer. 

    Letter of engagement sent to manufacturer

    This lets the manufacturer know the pCPA is ready to start negotiating.

  • Negotiation

    The pCPA negotiation team reaches out to the manufacturer to outline next steps, then we exchange offers to try to reach an agreement on terms and funding conditions.

  • Completion

    The pCPA creates a letter of intent outlining negotiated terms. If the negotiation ended without an agreement, the pCPA sends a letter letting the manufacturer know that the negotiation is closed. 

    Negotiation process concluded

Related negotiations

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT

Last updated:

November 18, 2021

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma, locally advanced unresectable or metastatic, in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients (First-line treatment)

Last updated:

February 11, 2022

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

High-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, in adult patients

Last updated:

October 7, 2022

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. (in combination with Lenvatinib (Lenvima))

Last updated:

May 12, 2023